April 8, 2025 – Talk Bio

Rocket Pharmaceuticals Expands Leadership with J&J and AstraZeneca Alumni to Strengthen Gene Therapy Commercialization

2 weeks ago talkbio0Tagged AstraZeneca, Biotechnology, Chaudhuri, commercial, gene therapy, Kresladi, launch, Market, Mozafancogene Autotemcel, Rocket, Sarbani

Rocket Pharmaceuticals, gene therapy, commercial leadership, Sarbani Chaudhuri, Johnson & Johnson, AstraZeneca, commercial launch, gene therapy market, rare diseases, biotechnology, Kresladi, RP-L102.

RFK Jr. promotes measles vaccine as Texas outbreak continues

2 weeks ago talkbio0Tagged Case (situation), Disease Outbreaks, Effectiveness, Measles, Measles-Mumps-Rubella Vaccine, RFK gene, Texas, Vaccination, Vaccines

Vaccines, Texas, Measles, Disease Outbreaks, Measles-Mumps-Rubella Vaccine, Case (situation), RFK gene, Effectiveness, Vaccination, Texas

U.S. Congressional Report Calls for $15 Billion to Bolster Biotech Leadership Amid Rising Chinese Competition

2 weeks ago talkbio0Tagged Bioeconomy, Biomanufacturing Strategy, Biotech Competition, Biotechnology, Biotechnology Advantage, China, Investments, National Security Commission, Tech Rivalry, U.S.-China, United States

U.S. Biotechnology Advantage, China Biotech Competition, National Security Commission on Emerging Biotechnology, Biotechnology Investment, Biomanufacturing Strategy, U.S.-China Tech Rivalry, Bioeconomy

Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots

2 weeks ago talkbio0Tagged Autoimmune, Autoimmune Diseases, Precision - temporal

Autoimmune, Autoimmune Diseases, Precision – temporal

Rallybio Halts Development of Lead FNAIT Program Following Phase 2 Failure

2 weeks ago talkbio0Tagged Alloimmune thrombocytopenia, Biotech pipeline shift, Fetal and neonatal alloimmune thrombocytopenia, Fetus, immune disorder therapy, Infant, Newborn, Mother (person), Phase 2 clinical trial, Rallybio RLYB212

Rallybio RLYB212, Fetal and neonatal alloimmune thrombocytopenia (FNAIT), Phase 2 clinical trial, Maternal immune disorder therapy, Biotech pipeline shift

Stock market melts down over Trumps tariffs, and biotech’s pain keeps growing

2 weeks ago talkbio0Tagged Investments, Market

Market, Investments

Cartesian reveals long-term mid-stage data for cell therapy in myasthenia gravis

2 weeks ago talkbio0Tagged Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes, Cartesian, Cell Therapy, Long-term, Myasthenia Gravis

Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes, Myasthenia Gravis, Cell Therapy, Long-term, Cartesian

DualityBio Pursues $200M IPO in Hong Kong Amid Volatile Market Conditions

2 weeks ago talkbio0Tagged Antibody-Drug, BioNTech, biotech sector, DualityBio, global trade tensions, Hong, Immunostimulating conjugate (antigen), Investments, IPO, Kong, Market, Stock exchange, upheaval

DualityBio, IPO, Hong Kong Stock Exchange, biotech investment, antibody-drug conjugates, BioNTech, market upheaval, global trade tensions, biotech sector growth.